InformationRadotinib Radotinib (IY-5511) is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia.TargetsBCR-ABL1 34 nMIn vitroRadotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. Radotinib also effectively inhibits the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. In AML cells, radotinib significantly decreases the cell viability, promotes differentiation, and induces CD11b expression and apoptosis. In NB4, THP-1, and Kasumi-1 cells, radotinib also induces CD11b expression, and decreases the viability.Cell Research(from reference)Cell lines：BMCs of AML and CML patients, NB4, HL60, KASUMI-1, and THP-1 cells Concentrations：~100 μM Incubation Time：72 h. Specification: 0.98 Molecular Formula: C27H21F3N8O Molecular Weight: 530.5 PubChem CID: 16063245 Isomeric SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5 Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/R413916-SCI_013df1f09c3db644e1f1158f9d7ba15f.pdf
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 2 weeks
- Weight:
- 0.96 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- R413916-25mg
- CAS:
- 926037-48-1
- Product Size:
- 25mg
- Hazard Statement Codes:
- H302:H315:H319:H335
- Precautionary Statement Codes:
- P261:P305+P351+P338
